Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis is committed to advancing its lead drug candidate, QINPREZO (vosaroxin), through clinical trials. QINPREZO is an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer.



Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1987
Size (employees)
37 (est)
Sunesis Pharmaceuticals was founded in 1987 and is headquartered in South San Francisco, US

Key People/Management at Sunesis Pharmaceuticals

Daniel Swisher

Daniel Swisher

Chief Executive Officer and President

Sunesis Pharmaceuticals Office Locations

Sunesis Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
395 Oyster Point Boulevard
Show all (1)

Sunesis Pharmaceuticals Financials and Metrics

Sunesis Pharmaceuticals Financials

USD

Market capitalization (16-Feb-2018)

141.4 m
Sunesis Pharmaceuticals's current market capitalization is $141.4 m.
Show all financial metrics

Sunesis Pharmaceuticals Market Value History

Sunesis Pharmaceuticals's Web-traffic and Trends

Sunesis Pharmaceuticals Company Life and Culture

You may also be interested in